Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Stanford Medicine, Seattle Cancer Care Alliance, University of Washington, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Fox Chase Cancer Center, Mount Vernon Cancer Centre, Medizinische Hochschule Hannover, Niigata University, Bristol-Myers Squibb (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2470929533